Malmö, Sweden

Salih Muhammed

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Niconovum Ab. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Salih Muhammed. Retrieved from https://idiyas.com/inventor/salih-muhammed

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Salih Muhammed: Innovator in Helsingborg

Introduction

Salih Muhammed is an inventor based in Helsingborg, Sweden. He is currently associated with Niconovum AB, a company known for its innovative approaches in the field of healthcare. Despite having no patents to his name, Salih's contributions to his field are noteworthy.

Latest Patents

As of now, Salih Muhammed holds 1 patents. This indicates that he may be in the early stages of his inventive journey or focusing on collaborative projects rather than individual patenting.

Career Highlights

Salih has made significant strides in his career at Niconovum AB. His work primarily revolves around developing solutions that enhance patient care and improve health outcomes. His dedication to innovation is evident in his daily tasks and responsibilities.

Collaborations

Salih collaborates closely with his coworker, Nelly Fransen. Together, they work on various projects that aim to push the boundaries of healthcare technology.

Conclusion

Salih Muhammed is an emerging inventor in Helsingborg, contributing to the innovative landscape at Niconovum AB. His journey in the field of invention is just beginning, and his future endeavors may lead to significant advancements in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…